Pro-Pharmaceuticals engages in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections.
Anatole Klyosov,chief scientist, Pro-Pharmaceuticals, said: “Collaborating with Brigham and Women’s Hospital represents an exciting opportunity to partner with a premier academic hospital to further explore the use of our novel compounds to treat kidney fibrosis.”
According to the National Kidney Foundation, approximately 12 million people suffer from kidney fibrosis.